Dr. Soliman Abdel Kader Fakeeh Hospital Valuation
Is 4017 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4017 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4017 (SAR57.9) is trading below our estimate of fair value (SAR135.75)
Significantly Below Fair Value: 4017 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4017?
Key metric: As 4017 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4017's PE Ratio? | |
|---|---|
| PE Ratio | 46.3x |
| Earnings | ر.س287.77m |
| Market Cap | ر.س13.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.2x |
| Enterprise Value/EBITDA | 29x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does 4017's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 26.2x | ||
4004 Dallah Healthcare | 31.4x | 14.2% | ر.س14.8b |
4002 Mouwasat Medical Services | 27.7x | 16.6% | ر.س18.2b |
4005 National Medical Care | 26.5x | 11.5% | ر.س7.3b |
4007 Al Hammadi Holding | 19.4x | 9.4% | ر.س6.3b |
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 46.3x | 20.0% | ر.س13.3b |
Price-To-Earnings vs Peers: 4017 is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the peer average (26.2x).
Price to Earnings Ratio vs Industry
How does 4017's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4017 is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the Asian Healthcare industry average (21x).
Price to Earnings Ratio vs Fair Ratio
What is 4017's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 46.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4017's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س57.90 | ر.س61.97 +7.0% | 9.1% | ر.س66.00 | ر.س50.00 | n/a | 6 |
| Nov ’25 | ر.س57.80 | ر.س61.97 +7.2% | 9.1% | ر.س66.00 | ر.س50.00 | n/a | 6 |
| Oct ’25 | ر.س59.10 | ر.س61.97 +4.9% | 9.1% | ر.س66.00 | ر.س50.00 | n/a | 6 |
| Sep ’25 | ر.س58.00 | ر.س64.36 +11.0% | 2.9% | ر.س66.00 | ر.س61.00 | n/a | 5 |
| Aug ’25 | ر.س59.40 | ر.س64.36 +8.4% | 2.9% | ر.س66.00 | ر.س61.00 | n/a | 5 |
| Jul ’25 | ر.س60.00 | ر.س64.25 +7.1% | 3.2% | ر.س66.00 | ر.س61.00 | n/a | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.